Skip to main content

Overview

Dr. Zoltan Antal is the Director of the Pediatric Diabetes Program in the Division of Pediatric Endocrinology, and an Assistant Professor of Pediatrics at Weill Cornell Medical College.  He is also an Assistant Attending Pediatrician at NewYork-Presbyterian Hospital.  He is board certified in Pediatrics and Pediatric Endocrinology.
 
Dr. Antal received a B.S. in Biology from Stony Brook University in Stony Brook, New York and completed his medical degree (M.D.) from St. George’s University School of Medicine in Grenada, West Indies in combination with clinical rotations at Jamaica Hospital in Queens, New York City. He went on to complete his Residency in Pediatrics in Brooklyn, New York at SUNY Downstate Medical Center and Kings County Hospital, where he later served as chief resident. After residency, he remained in New York City and completed a fellowship in Pediatric Endocrinology at the Children’s Hospital at Montefiore in the Bronx.
 
During his fellowship, Dr. Antal also conducted research at the Albert Einstein College of Medicine in the immunology of diabetes. Specifically, he isolated islet cells from pancreata of diabetic mice and studied the targets of the islet infiltrating T cells. In addition, he was also in charge of the translational component of the research, which entailed examining the peripheral blood of children newly diagnosed with type 1 diabetes, searching for reactivity to the human counterparts of the murine T cell targets.
 
Finally, Dr. Antal and his colleagues analyzed the HLA supertypes of a subset of diabetic children, publishing the findings in the Annals of the New York Academy of Sciences in 2008.

Highlights

  1. 1
    Pediatric blood & cancer · 2023
    PMID: 38149843PMCID: PMC10843544DOISenior author3 citations

Publications

39 publications

Funding

2 grants

Active

2 grants
  • Co-I
    Abnormal Extracellular Vesicles and Particles from Human Islets Impact T1D progression
    National Institute of Diabetes and Digestive and Kidney Diseases · 2023–2028
    R01DK137517-04
  • PI
    T1D Exchange Quality Improvement (QI) Initiative
    T1D Exchange · 2020–2026Contract
    SRA 212039-02

Clinical research

1 study
Completed & closed trials (1)
  • PI
    Environmental bisphenols and risk of Hypospadias
    Columbia University · CLOSED TO ACCRUAL (as of 2024)

News mentions

External relationships

Other

Bayer Healthcare Pharmaceuticals